SCHEDULE: Morgan Stanley Discloses 8.6% Stake in Beta Bionics

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, disclosing beneficial ownership of 8.6% of Beta Bionics, Inc.'s common stock.

Summary

• Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley Capital Services LLC, collectively beneficially own 3,739,567 shares of Beta Bionics, Inc. common stock.
• This aggregate ownership represents 8.6% of the total class of Beta Bionics, Inc. common stock.
• Morgan Stanley, as a parent holding company, reports shared voting power over 3,737,581 shares and shared dispositive power over 3,739,567 shares.
• Morgan Stanley Capital Services LLC separately reports shared voting power and shared dispositive power over 3,384,256 shares, which constitutes 7.8% of the class.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Beta Bionics, Inc.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a routine disclosure of passive institutional ownership and typically has a neutral sentiment unless it signals a new activist stake or a significant change in investment thesis, which is not indicated here.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional stake by Morgan Stanley in Beta Bionics, a common occurrence for publicly traded companies where large financial institutions hold shares for clients or through various investment vehicles. It reflects Morgan Stanley's role as a major financial services provider and broker-dealer.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a passive investment intent.

Key Dates

Keywords

Beta Bionics, Morgan Stanley, Morgan Stanley Capital Services LLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, SEC Filing, Investment